Latest News for: sirna

Edit

Small Interfering RNA (siRNA) Therapeutics Market 2021 Key Players and Production Information Analysis with Forecast 2027

MENA FN 01 Nov 2021
(MENAFN - Ameliorate Solutions) Posted on November 1, 2021 by Market Insights Reports Small Interfering RNA (siRNA) Therapeutics Market 2021 Key Players and Production Information Analysis with ... .
Edit

Clinical Overview of AB-729, a potent siRNA in development for the treatment of chronic hepatitis B infection (Arbutus Biopharma Corp)

Public Technologies 14 Oct 2021
). Clinical Overview of AB-729, a potent siRNA in development for the treatment of chronic hepatitis B infection. Dr. Gaston Picchio. Chief Development Officer. The Science of HBV Cure Meeting 2021 ONLINE. October 11-15, 2021. NASDAQ. ABUS www.arbutusbio.com. AB-729-001 Study Overview. Part 1. Single Ascending Dose in Healthy Subjects. Part 2. Single Doses in.
Edit

Alnylam and PeptiDream Enter into Collaboration Agreement to Discover and Develop Peptide-siRNA Conjugates for Targeted ...

Business Wire 29 Jul 2021
... peptide-siRNA conjugates to create multiple opportunities to deliver RNAi therapeutics to tiss .
Edit

Alnylam and PeptiDream Enter into Collaboration Agreement to Discover and Develop Peptide-siRNA Conjugates for Targeted Delivery of RNAi Therapeutics to a Broader Range of Extrahepatic Tissues (Alnylam Pharmaceuticals Inc)

Public Technologies 29 Jul 2021
Alnylam and PeptiDream Enter into Collaboration Agreement to Discover and Develop Peptide-siRNA Conjugates for Targeted Delivery of RNAi Therapeutics to a Broader Range of Extrahepatic Tissues ... Alnylam will then generate peptide-siRNA conjugates and perform in vitro and in vivo studies to support final peptide selection.
Edit

Synthetic siRNA Market Glorious Boom by 2028| Dharmacon (ThermoFisher), Invitrogen, Integrated DNA Technologies, MWG Biotech, ...

The Sentinel Newspaper 23 Jun 2021
Small interfering RNA (siRNA) is a powerful tool for modulating gene expression by RNA interference (RNAi) ... The siRNA is then incorporated into a multi-subunit protein complex called RNAi-induced silencing complex (RISC) ... siRNAs can now be obtained in various ways allowing for numerous in vitro and in vivo applications.
Edit

Auris Medical Announces Significant Inhibition of Tumor Growth with OligoPhore siRNA Targeting NF-κB in Murine ...

Nasdaq Globe Newswire 22 Jun 2021
... of tumor growth by siRNA knock-down of NF-κB employing its OligoPhoreTM technology in Adult T-cell Leukemia Lymphoma (ATLL).
Edit

Horizon to receive a worldwide exclusive license for an investigational short interfering RNA (siRNA) therapeutic targeting xanthine dehydrogenase (XDH) (Form 8-K) (Arrowhead Pharmaceuticals Inc)

Public Technologies 22 Jun 2021
). - Horizon to receive a worldwide exclusive license for an investigational short interfering RNA (siRNA) therapeutic targeting xanthine dehydrogenase (XDH) ... (NASDAQ. ARWR) and Horizon Therapeutics plc (NASDAQ ... Under the terms of the agreement, Arrowhead will conduct all activities through preclinical stages of development of the siRNA therapeutic.
Edit

Auris Medical Announces Significant Inhibition of Tumor Growth with OligoPhore siRNA Targeting NF-κB in Murine Model of Adult T-Cell Leukemia / Lymphoma (Auris Medical Holding Ltd)

Public Technologies 21 Jun 2021
) Treatment with OligoPhoreTM siRNA stops aggressive ATLL tumor growth to near zero Significant reduction in tumor size, spleen size and peripheral blood lymphocyte counts Results add to extensive body of evidence for effective OligoPhoreTM enabled delivery of nucleic acids to extrahepatic tissues.
Edit

TRANSHUMANISM brain interface siRNA D-WAVE covid19 connection

Bitchute 18 Jun 2021
Go to the source via the link below to view the video ....
Edit

Chemical changes to peptide siRNA-carrier enhance gene silencing for future cancer drugs

Science Daily 25 May 2021
Researchers found a modified peptide carrier that was delivering the siRNA drug by adhering to and potentially moving along cell filopodia, leading to more efficient cell entry and improved gene silencing. <!-- more --> ... .
Edit

Silence Therapeutics Receives Remaining $40 Million from AstraZeneca as Part of Upfront Investment for Ongoing siRNA Collaboration (Form 6-K) (Silence Therapeutics plc)

Public Technologies 25 May 2021
Silence Therapeutics Receives Remaining $40 Million from AstraZeneca as Part of Upfront Investment for Ongoing siRNA Collaboration ... The collaboration is focused on leveraging Silence's proprietary mRNAi GOLD™ platform to discover and develop siRNA therapeutics for cardiovascular, renal, metabolic (CVRM) and respiratory diseases.
Edit

RUBICON lockstep into TRANSHUMANISM brain interface siRNA D-WAVE covid19 connection

Bitchute 11 May 2021
Go to the source via the link below to view the video..
×